Key facts
- This page summarizes Sofinnova Partners SAS's Form 3 filing for CinCor Pharma, Inc..
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Jan 2022, 19:56.
Sofinnova Partners SAS - 06 Jan 2022 Form 3 Insider Report for CinCor Pharma, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 06 Jan 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Jan 2022, 19:56:08 UTC
- Next SEC filing
- 13 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- Sofinnova Partners SAS, By Monique Saulnier, Managing Partner
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sofinnova Partners SAS filed Form 3 for CinCor Pharma, Inc. on 06 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CINC
holding
Derivative
Series A Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Jan 2022
- Ownership
- By Sofinnova Capital IX
- Underlying class
- Common Stock
- Underlying amount
- 2,941,176
- Exercise price
- Footnotes
- F1, F2
CINC
holding
Derivative
Series B Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Jan 2022
- Ownership
- By Sofinnova Capital IX
- Underlying class
- Common Stock
- Underlying amount
- 926,470
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
Footnote F2
The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.